|
Post by notamnkdmillionaire on Aug 7, 2014 20:53:49 GMT -5
I think the fact that AMPH bought the facility from Merck is interesting, I don't think that it telegraphs anything about a deal with Merck. We will have to find out on Monday what the story is, assuming there is anything to tell. For some reason, I have a feeling we might not like what management tells us.
|
|
|
Post by roozle on Aug 8, 2014 21:54:54 GMT -5
I'm not exactly sure where I should post this info - so forgive my (potential) lack of decorum...
I grew up near a Merck Facility in Danville, PA...and a few years ago they sold their entire Danville Operations to Cherokee Pharmaceuticals. Cherokee ran the plant for a few years and leaned out the staffing, then Merck bought everything back, expanded capabilities (I believe) and hired in more staff.
Rumor in the area at the time was that Merck bought it back for what they had sold it for, and that was said to be part of the plan when they first sold to Cherokee - as if it were a temporary stewardship by Cherokee.
I know this has no direct relevance to the Amphastar deal, but it may give some insight into how far down the road Merck actually plans.
mnkdmillionare - I thought I'd pass this on to you since you seem so diligent in your posts!
|
|
|
Post by kc on Aug 9, 2014 18:32:58 GMT -5
The answer to the holy grail is buried in the SEC filings of AMPH. The grail is found in the July 3rd filing. Do the research and see where the trail begins and ends. It led me to Merck & mannKind. Anybody like like the caymans.
|
|
|
Post by BD on Aug 9, 2014 18:58:24 GMT -5
Anybody like like the caymans. I prefer the Boxsters
|
|
|
Post by liane on Aug 9, 2014 19:00:42 GMT -5
So I see a 13G for Deerfield (various funds) and another for Broadfin Capital / Broadfin Healthcare. Where does Merck fit in?
|
|
|
Post by a1nb2p on Aug 9, 2014 19:56:01 GMT -5
Anybody like like the caymans. I prefer the Boxsters I'm more of a Panamera guy, myself.
|
|
|
Post by mnholdem on Aug 9, 2014 20:54:05 GMT -5
The answer to the holy grail is buried in the SEC filings of AMPH. The grail is found in the July 3rd filing. Do the research and see where the trail begins and ends. It led me to Merck & mannKind. Anybody like like the caymans. I'm heading into SEC filings in a mo'... while I'm catching up, morningstar shows Deerfield Management is one of the major institutional owners of Amphastar, with over 1.8 million shares. So what do you think that implies?
|
|
|
Post by spiro on Aug 9, 2014 21:17:08 GMT -5
It's hard to connect the dots after one has overdosed on ouzo. When you guys finish connecting everything and have it all figured out, let me know. I may have to go to detective school before this thing is over. But for now, I am still singing Monday Monday.
Spiro
|
|
|
Post by mnholdem on Aug 9, 2014 21:25:58 GMT -5
Interesting. At least two major AMPH shareholders with voting rights that have ties to Al Mann. Deerfield & Broadfin Capital. Kevin Kotler, who manages Broadfin, formerly served as a member of the selection committee for the Alfred Mann Foundation for Biomedical Engineering (2005-2008), which established technology centers at the University of Southern California, Purdue University and the Technion.
Both Deerfield & Broadfin came on board Amphastar during the last week of June 2014.
I haven't found the Merck connection, though.
Spiro, any of the ouzo left?
|
|
|
Post by kc on Aug 9, 2014 21:43:57 GMT -5
BINGO. YOU WIN THE GAME. I wonder who bought the majority of the Amphastar shares. I guess in time we will know. A lot of coincidental things happening. Kotlar's ties. Why was there a SEC CT-order issued on the stock? AMPHASTAR PHARMACEUTICALS, INC. CT ORDER 6/25/2014 N/A Was the Confidential treatment order placed to protect the integrity the entire planned transaction?
The he entire transaction was a preplanned event. With all the parties involved. If you go back to many of the transcripts it always seemed that Mann and the executive team had a plan and kept stating the timing was six to eight weeks after FDA approval.
The IPO occurred and remarkably was over sold. OVER-ALLOTMENT How nice is that for the underwriters.
Amphastar Pharmaceuticals Announces Exercise of Over-Allotment Option Amphastar Pharmaceuticals, Inc. Jun 30, 2014 6:00 AM GlobeNewswire RANCHO CUCAMONGA, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Amphastar) (Nasdaq:AMPH), a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and inhalation products, today announced that the underwriters of its initial public offering exercised in full their option to purchase from Amphastar 1,200,000 additional shares of its common stock at the initial public offering price of $7.00 per share.
Including the exercise of the over-allotment option, Amphastar has sold a total of 5,840,000 shares of its common stock, which represents a total capital raise of approximately $40.9 million before deducting underwriting discounts and commissions, and offering expenses payable by Amphastar. The selling stockholder named in the registration statement has sold a total of 3,360,000 shares of Amphastar's common stock. Amphastar did not receive any proceeds from the sale of the shares by the selling stockholder.
Jefferies LLC, BMO Capital Markets Corp. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager. The offering of these shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus relating to the offering, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com; BMO Capital Markets Corp., Attention Equity Syndicate Department, 3 Times Square, 27th Floor, New York, NY 10036, telephone: (800) 414-3627, email: bmoprospectus@bmo.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, telephone: (800) 747-3924, email: prospectus@pjc.com.
so in closing my view is that Merck will be involved in Afrezza in some manner going forward. Am I right or wrong. We will see soon.
I am long and hopeful.
|
|
|
Post by notatool on Aug 10, 2014 0:23:57 GMT -5
Hey People....I posted this on the other thread a few days ago........ Help please. I was just looking at some relationships trying to examine supply chains, customer chains and partners. You all may already know this since I am new to the game but I came across Deerfield Management Company L.P. (specifically James E. Flynn) taking a 1.83 share position in AMPH on or about July 1, 2014. I looked further and Deerfield Private Design Fund II L.P. as well as the International II L.P. (Mannkind's Source) are under the same umbrella. Why (how ethically) did the other "arm" take a big stake in AMPH shortly after Afrezza FDA approval and near the time MNKD drew the last tranche? I am looking to see what else Deerfield suddenly took a bite of. THANKS Read more: mnkd.proboards.com/thread/1105/interesting-broker-experience-amph#ixzz39xoaGDER
|
|
|
Post by mnholdem on Aug 10, 2014 10:27:21 GMT -5
Hey People....I posted this on the other thread a few days ago........ Help please. I was just looking at some relationships trying to examine supply chains, customer chains and partners. You all may already know this since I am new to the game but I came across Deerfield Management Company L.P. (specifically James E. Flynn) taking a 1.83 share position in AMPH on or about July 1, 2014. I looked further and Deerfield Private Design Fund II L.P. as well as the International II L.P. (Mannkind's Source) are under the same umbrella. Why (how ethically) did the other "arm" take a big stake in AMPH shortly after Afrezza FDA approval and near the time MNKD drew the last tranche? I am looking to see what else Deerfield suddenly took a bite of. THANKS Read more: mnkd.proboards.com/thread/1105/interesting-broker-experience-amph#ixzz39xoaGDERI remember it. You got me pointed in the direction of Al acquiring Amphastar. We've all been more focused on the partner. AMPH plays in to Al's plans later, I think...
|
|
|
Post by mnholdem on Aug 10, 2014 10:33:30 GMT -5
Deerfield & Broadfin together account for about 10% voting stock, and since AMPH was the primary insulin supplier for Afrezza trials, Al may have close ties with insiders there as well.
|
|
|
Post by dreamboatcruise on Aug 10, 2014 11:46:06 GMT -5
Hey People....I posted this on the other thread a few days ago........ Help please. I was just looking at some relationships trying to examine supply chains, customer chains and partners. You all may already know this since I am new to the game but I came across Deerfield Management Company L.P. (specifically James E. Flynn) taking a 1.83 share position in AMPH on or about July 1, 2014. I looked further and Deerfield Private Design Fund II L.P. as well as the International II L.P. (Mannkind's Source) are under the same umbrella. Why (how ethically) did the other "arm" take a big stake in AMPH shortly after Afrezza FDA approval and near the time MNKD drew the last tranche? I am looking to see what else Deerfield suddenly took a bite of. THANKS Read more: mnkd.proboards.com/thread/1105/interesting-broker-experience-amph#ixzz39xoaGDEREthics don't really play into that, it is either insider trading or it is not. In this case it was no secrete where MNKD got their insulin for the trials. Given the timeline for FDA approval of a new insulin supplier it may simply have been a logical conclusion that Mannkind would be buying from this source for quite some time. I'm not discounting the possibility they knew non public information, but I don't see a smoking gun here.
|
|
|
Post by liane on Aug 10, 2014 13:28:24 GMT -5
|
|